No Prescription |
 |
 | ||
|
Prescription Drugs 2 |
|
| ||
No Prescription » Prescription Drugs 2
Apcalis SX Oral Jelly Orange Flavor Cialis Apo Ipravent Nasal Spray Atrovent Asacol Enema Generic Mesalazine Atrovent Inhaler Generic Ipratropium bromide Augmentin BID Suspension Generic Amoxicillin trihydrate Augmentin Generic Amoxicillin trihidrate Augmentin Syrup Generic Amoxicillin trihydrate AVIL Generic Pheniramine Maleate Azopt Eye Drops Generic Brinzolamide Baclazone INHLR Generic Beclometasone Bactroban Ointment Generic Mupirocin Becoderm C Generic Clobetasone Butyrate Beconase Hayfever Generic Beclomethasone Dipropionate Becozyme C Fort Generic Vitamin B Benadryl Cough Forte Chesty Genahist Benadryl Cough Forte Dry Genahist Benadryl Cough Nasal Chesty Genahist Benadryl Dry Cough Nasal Congest Genahist
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|